Identification of a non-Gatekeeper hot spot for drug-resistant mutations in mTOR kinase

Cell Reports

Volumn 11, Issue 3, 2015, Pages 446-459

  Wu, Tzung Ju ^a,b   Wang, Xiaowen ^a,b   Zhang, Yanjie ^a   Meng, Linghua ^a   Kerrigan, John E ^a   Burley, Stephen K ^b   Zheng, X F Steven ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG RESISTANCE; ENZYME STRUCTURE; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HYDROPHOBICITY; LUNG CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; GENETICS; METABOLISM; MUTATION; NUDE MOUSE; PHYSIOLOGY; SACCHAROMYCES CEREVISIAE; SITE DIRECTED MUTAGENESIS; TUMOR CELL LINE; XENOGRAFT;

PYRONIA TITHONUS;

ANIMALS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; HETEROGRAFTS; HUMANS; MICE; MICE, NUDE; MUTAGENESIS, SITE-DIRECTED; MUTATION; SACCHAROMYCES CEREVISIAE; TOR SERINE-THREONINE KINASES;

EID: 84928209828     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.03.040     Document Type: Article

References (60)

1. Alarcon C.M., Cardenas M.E., Heitman J. Mammalian RAFT1 kinase domain provides rapamycin-sensitive TOR function in yeast. Genes Dev. 1996, 10:279-288.
2. Azam M., Latek R.R., Daley G.Q. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003, 112:831-843.
3. Bell D.W., Gore I., Okimoto R.A., Godin-Heymann N., Sordella R., Mulloy R., Sharma S.V., Brannigan B.W., Mohapatra G., Settleman J., Haber D.A. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat. Genet. 2005, 37:1315-1316.
4. Bjornsti M.-A., Houghton P.J. The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer 2004, 4:335-348.
5. Chen J., Zheng X.F., Brown E.J., Schreiber S.L. Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. Proc. Natl. Acad. Sci. USA 1995, 92:4947-4951.
6. Cong L., Ran F.A., Cox D., Lin S., Barretto R., Habib N., Hsu P.D., Wu X., Jiang W., Marraffini L.A., Zhang F. Multiplex genome engineering using CRISPR/Cas systems. Science 2013, 339:819-823.
7. Dohmen R.J., Varshavsky A. Heat-inducible degron and the making of conditional mutants. Methods in Enzymology 2005, 799-822. Academic Press. J.D. Raymond (Ed.).
8. Dunstan H.M., Ludlow C., Goehle S., Cronk M., Szankasi P., Evans D.R., Simon J.A., Lamb J.R. Cell-based assays for identification of novel double-strand break-inducing agents. J.Natl. Cancer Inst. 2002, 94:88-94.
9. Emter R., Heese-Peck A., Kralli A. ERG6 and PDR5 regulate small lipophilic drug accumulation in yeast cells via distinct mechanisms. FEBS Lett. 2002, 521:57-61.
10. Engelman J.A., Mukohara T., Zejnullahu K., Lifshits E., Borrás A.M., Gale C.M., Naumov G.N., Yeap B.Y., Jarrell E., Sun J., et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J.Clin. Invest. 2006, 116:2695-2706.
11. Feldman M.E., Apsel B., Uotila A., Loewith R., Knight Z.A., Ruggero D., Shokat K.M. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 2009, 7:e38.
12. Gaber R.F., Copple D.M., Kennedy B.K., Vidal M., Bard M. The yeast gene ERG6 is required for normal membrane function but is not essential for biosynthesis of the cell-cycle-sparking sterol. Mol. Cell. Biol. 1989, 9:3447-3456.
13. Ghannoum M.A., Rice L.B. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin. Microbiol. Rev. 1999, 12:501-517.
14. Gild M.L., Landa I., Ryder M., Ghossein R.A., Knauf J.A., Fagin J.A. Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells. Endocr. Relat. Cancer 2013, 20:659-667.
15. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., Sawyers C.L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293:876-880.
16. Gray N.S., Wodicka L., Thunnissen A.-M.W.H., Norman T.C., Kwon S., Espinoza F.H., Morgan D.O., Barnes G., LeClerc S., Meijer L., et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 1998, 281:533-538.
17. Guertin D.A., Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12:9-22.
18. Guertin D.A., Sabatini D.M. The pharmacology of mTOR inhibition. Sci. Signal. 2009, 2:pe24.
19. Hayman T.J., Wahba A., Rath B.H., Bae H., Kramp T., Shankavaram U.T., Camphausen K., Tofilon P.J. The ATP-competitive mTOR inhibitor INK128 enhances invitro and invivo radiosensitivity of pancreatic carcinoma cells. Clin. Cancer Res. 2014, 20:110-119.
20. Heinrich M.C., Corless C.L., Demetri G.D., Blanke C.D., von Mehren M., Joensuu H., McGreevey L.S., Chen C.J., Van den Abbeele A.D., Druker B.J., et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J.Clin. Oncol. 2003, 21:4342-4349.
21. Hsieh A.C., Liu Y., Edlind M.P., Ingolia N.T., Janes M.R., Sher A., Shi E.Y., Stumpf C.R., Christensen C., Bonham M.J., et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 2012, 485:55-61.
22. Hu J., Yu H., Kornev A.P., Zhao J., Filbert E.L., Taylor S.S., Shaw A.S. Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF. Proc. Natl. Acad. Sci. USA 2011, 108:6067-6072.
23. Hu J., Stites E.C., Yu H., Germino E.A., Meharena H.S., Stork P.J., Kornev A.P., Taylor S.S., Shaw A.S. Allosteric activation of functionally asymmetric RAF kinase dimers. Cell 2013, 154:1036-1046.
24. Kennedy E.J., Yang J., Pillus L., Taylor S.S., Ghosh G. Identifying critical non-catalytic residues that modulate protein kinase A activity. PLoS ONE 2009, 4:e4746.
25. Kobayashi S., Boggon T.J., Dayaram T., Jänne P.A., Kocher O., Meyerson M., Johnson B.E., Eck M.J., Tenen D.G., Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N.Engl. J. Med. 2005, 352:786-792.
26. Kornev A.P., Haste N.M., Taylor S.S., Eyck L.F. Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proc. Natl. Acad. Sci. USA 2006, 103:17783-17788.
27. Liu Y., Gray N.S. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2006, 2:358-364.
28. Liu Q., Ren T., Fresques T., Oppliger W., Niles B.J., Hur W., Sabatini D.M., Hall M.N., Powers T., Gray N.S. Selective ATP-competitive inhibitors of TOR suppress rapamycin-insensitive function of TORC2 in Saccharomyces cerevisiae. ACS Chem. Biol. 2012, 7:982-987.
29. Loewith R., Jacinto E., Wullschleger S., Lorberg A., Crespo J.L., Bonenfant D., Oppliger W., Jenoe P., Hall M.N. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell 2002, 10:457-468.
30. Ma X.M., Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat. Rev. Mol. Cell Biol. 2009, 10:307-318.
31. Mali P., Yang L., Esvelt K.M., Aach J., Guell M., DiCarlo J.E., Norville J.E., Church G.M. RNA-guided human genome engineering via Cas9. Science 2013, 339:823-826.
32. Martzen M.R., McCraith S.M., Spinelli S.L., Torres F.M., Fields S., Grayhack E.J., Phizicky E.M. A biochemical genomics approach for identifying genes by the activity of their products. Science 1999, 286:1153-1155.
33. Meharena H.S., Chang P., Keshwani M.M., Oruganty K., Nene A.K., Kannan N., Taylor S.S., Kornev A.P. Deciphering the structural basis of eukaryotic protein kinase regulation. PLoS Biol. 2013, 11:e1001680.
34. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., Lane H., Hofmann F., Hicklin D.J., Ludwig D.L., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006, 66:1500-1508.
35. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., Kris M.G., Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005, 2:e73.
36. Ran F.A., Hsu P.D., Wright J., Agarwala V., Scott D.A., Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 2013, 8:2281-2308.
37. Sancak Y., Thoreen C.C., Peterson T.R., Lindquist R.A., Kang S.A., Spooner E., Carr S.A., Sabatini D.M. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol. Cell 2007, 25:903-915.
38. Santos F.P., Kantarjian H., Cortes J., Quintas-Cardama A. Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia. Curr. Opin. Investig. Drugs 2010, 11:1450-1465.
39. Sarbassov D.D., Ali S.M., Kim D.H., Guertin D.A., Latek R.R., Erdjument-Bromage H., Tempst P., Sabatini D.M. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 2004, 14:1296-1302.
40. Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098-1101.
41. Shaw A.S., Kornev A.P., Hu J., Ahuja L.G., Taylor S.S. Kinases and pseudokinases: lessons from RAF. Mol. Cell. Biol. 2014, 34:1538-1546.
42. Simon J.A., Bedalov A. Yeast as a model system for anticancer drug discovery. Nat. Rev. Cancer 2004, 4:481-492.
43. Sturgill T.W., Hall M.N. Activating mutations in TOR are in similar structures as oncogenic mutations in PI3KCalpha. ACS Chem. Biol. 2009, 4:999-1015.
44. Sun S.Y., Rosenberg L.M., Wang X., Zhou Z., Yue P., Fu H., Khuri F.R. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 2005, 65:7052-7058.
45. Taylor S.S., Kornev A.P. Protein kinases: evolution of dynamic regulatory proteins. Trends Biochem. Sci. 2011, 36:65-77.
46. Thoreen C.C., Kang S.A., Chang J.W., Liu Q., Zhang J., Gao Y., Reichling L.J., Sim T., Sabatini D.M., Gray N.S. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J.Biol. Chem. 2009, 284:8023-8032.
47. Tokarski J.S., Newitt J.A., Chang C.Y.J., Cheng J.D., Wittekind M., Kiefer S.E., Kish K., Lee F.Y.F., Borzillerri R., Lombardo L.J., et al. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 2006, 66:5790-5797.
48. Tsang C.K., Qi H., Liu L.F., Zheng X.F. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov. Today 2007, 12:112-124.
49. Uetz P., Giot L., Cagney G., Mansfield T.A., Judson R.S., Knight J.R., Lockshon D., Narayan V., Srinivasan M., Pochart P., et al. A comprehensive analysis of protein-protein interactions in Saccharomyces cerevisiae. Nature 2000, 403:623-627.
50. Vichai V., Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat. Protoc. 2006, 1:1112-1116.
51. Vogt P.K. Drug-resistant phosphatidylinositol 3-kinase: guidance for the preemptive strike. Cancer Cell 2008, 14:107-108.
52. Wood L.D., Parsons D.W., Jones S., Lin J., Sjöblom T., Leary R.J., Shen D., Boca S.M., Barber T., Ptak J., et al. The genomic landscapes of human breast and colorectal cancers. Science 2007, 318:1108-1113.
53. Wullschleger S., Loewith R., Hall M.N. TOR signaling in growth and metabolism. Cell 2006, 124:471-484.
54. Yang H., Rudge D.G., Koos J.D., Vaidialingam B., Yang H.J., Pavletich N.P. mTOR kinase structure, mechanism and regulation. Nature 2013, 497:217-223.
55. Zhang Y., Zheng X.F. mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors. Cell Cycle 2012, 11:594-603.
56. Zhang J., Yang P.L., Gray N.S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 2009, 9:28-39.
57. Zhang Y.-J., Bao Y.-J., Dai Q., Yang W.-Y., Cheng P., Zhu L.-M., Wang B.-J., Jiang F.-H. mTOR signaling is involved in indomethacin and nimesulide suppression of colorectal cancer cell growth via a COX-2 independent pathway. Ann. Surg. Oncol. 2011, 18:580-588.
58. Zhang Y.J., Duan Y., Zheng X.F. Targeting the mTOR kinase domain: the second generation of mTOR inhibitors. Drug Discov. Today 2011, 16:325-331.
59. Zheng X.F., Florentino D., Chen J., Crabtree G.R., Schreiber S.L. TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin. Cell 1995, 82:121-130.
60. Zunder E.R., Knight Z.A., Houseman B.T., Apsel B., Shokat K.M. Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha. Cancer Cell 2008, 14:180-192.